Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26244808 | 0.91 | HTR2A (0.46) | HTR2AMAPTPDE7AL3MBTL1RAB9A | |
| SCHEMBL26244791 | 0.89 | HTR2A (0.47) | HTR2AMAPTPDE7AL3MBTL1RAB9A | |
| SCHEMBL7164084 | 0.77 | HTR2A (0.64) | HTR2AMAPTPDE7AL3MBTL1RAB9A | |
| SCHEMBL120371 | 0.76 | HTR2A (0.49) | HTR2AMAPTRAB9AGAAKDM4E | |
| SCHEMBL9846652 | 0.76 | HTR2A (0.54) | HTR2AMAPTGAAALDH1A1HTT | |
| SCHEMBL30679539 | 0.76 | HTR2A (0.62) | HTR2AMAPTPDE7AL3MBTL1RAB9A | |
| SCHEMBL7519250 | 0.74 | HTR2A (0.55) | HTR2AGAAALDH1A1HTTKMT2A | |
| SCHEMBL6594172 | 0.74 | HTR2A (0.74) | HTR2AMAPTL3MBTL1RAB9AGAA | |
| SCHEMBL5022220 | 0.74 | HTR2A (0.63) | HTR2AMAPTPDE7ARAB9AGAA | |
| SCHEMBL29462425 | 0.74 | SMN1; SMN2 (0.55) | HTR2AMAPTRAB9AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | MAVERIX ONCOLOGY, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| WO-2019152955-A9 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-2857018-A1 | Treatment or prophylaxis of proliferative conditions | University Court of The University of Dundee (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2015-01-08 | — | — | US | disclosed |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2424524-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | HTR2A 2118/4885MAPT 4538/4885PDE7A 1793/4885 |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | HTR2A 2383/4885MAPT 4494/4885PDE7A 1552/4885 |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | ZYX, KRAS, SLC7A5 | HTR2A 4217/4885MAPT 4676/4885PDE7A 1672/4885 |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | HTR2A 2118/4885MAPT 4538/4885PDE7A 1793/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | HTR2A 2383/4885MAPT 4494/4885PDE7A 1552/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | HTR2A 2383/4885MAPT 4494/4885PDE7A 1552/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | HTR2A 4143/4885MAPT 4486/4885PDE7A 265/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | HTR2A 2049/4885MAPT 4488/4885PDE7A 1487/4885 |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | ZYX, SLC7A5, GMPS | HTR2A 4138/4885MAPT 4465/4885PDE7A 285/4885 |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | HTR2A 2121/4885MAPT 4628/4885PDE7A 1182/4885 |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | HTR2A 2383/4885MAPT 4494/4885PDE7A 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.